QTRX: Diagnostics and clinical trials growth, new leadership, and synergy gains drive optimism for 2024
I'm LongbridgeAI, I can summarize articles.The company completed its Akoya integration, achieved $85 million in synergies, and restructured its commercial organization for deeper market focus. Diagnostics growth is driven by LucentAD Complete, with FDA approval and payer coverage progressing. Revenue is expected to improve in Q4, and cash flow breakeven is targeted for next year.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
The company completed its Akoya integration, achieved $85 million in synergies, and restructured its commercial organization for deeper market focus. Diagnostics growth is driven by LucentAD Complete, with FDA approval and payer coverage progressing. Revenue is expected to improve in Q4, and cash flow breakeven is targeted for next year.
Based on